Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced publication of complete results from a pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M™ adjuvant, in The Lancet Infectious Diseases (Lancet ID).

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

Novavax Inc. (NASDAQ:NVAX) shares are rallying after the company announced it finalized an advanced purchase agreement with the European Commission for the purchase of up to 200 million doses of its COVID-19 vaccine. Novavax is up 11.72% at $259.20 at publication time.

Why Novavax Looks Like It's Breaking Out Of A Pattern

NVAX stock is moving up today on plans to distribute its vaccine abroad. Even after failing to file with the FDA, investors are bullish.

NVAX Stock: The Big Covid-19 News Sending Novavax Shooting Higher

Novavax Inc (NASDAQ: NVAX) is trading significantly higher Thursday after the company, along with Serum Institute, announced a submission to the World Health Organization for emergency use listing for Novavax's COVID-19 vaccine candidate. Emergency use listing is a prerequisite for exports to multiple countries.

Why Novavax Shares Are Surging Higher Today

Novavax Inc (NASDAQ: NVAX) and its partner Serum Institute of India Pvt. Ltd. (SII) have announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.

Novavax Shares Gain After Filing With Serum Institute For WHO Emergency Use Listing For COVID-19 Vaccine

Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt.

Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine

GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference.

Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference

Are you familiar with the saying, “A watched pot never boils?” Owners of NVAX stock are likely very familiar and not happy about it.

Novavax Stock Will Reward the Very Patient in the Long Term

Amazon

Starbucks

General economic worries today don't change the big picture for these companies.

September Sell-Off: Best Stocks to Buy Now

Novavax (NVAX) closed at $230.29 in the latest trading session, marking a +1.49% move from the prior day.

Novavax (NVAX) Gains As Market Dips: What You Should Know

Novavax is a strong vaccine contender and the demand for vaccines is not going to slow down till next year. Buy NVAX stock in the dip.

Novavax Stock Has at Least Two Important Things Going for It

GAITHERSBURG, Md., Sept. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J.

Novavax to Participate in Fireside Chat at Devex @ UNGA 76

Novavax's combination vaccine and its Covid-19 vaccine sales for Q1/2022 in Japan are positive drivers for its revenue in the years ahead. The post Developed World Boosters Offer Big Market for Eventual Novavax Vaccine appeared first on InvestorPlace.

Developed World Boosters Offer Big Market for Eventual Novavax Vaccine

Dynavax Technologies

GlaxoSmithKline

Inovio Pharmaceuticals

Sanofi

Their vaccines could be late to the party. But the stocks might still be big winners.

5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch

BioNTech SE

Moderna

Ocugen, Inc.

Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.

Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising

GAITHERSBURG, Md., Sept. 16, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 3 (Com-COV3), led by the University of Oxford and funded by the UK Vaccines Taskforce (VTF) and the National Institute for Health Research (NIHR).

Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents

Novavax secured a supply agreement with the European Union, which is a sign of confidence for its vaccine. NVAX stock could move higher from here.

With the European Union Buying Doses, Novavax Has Plenty of Upside Left

Novavax is evaluated for its progress and the extent to which it has achieved success. The perception that the COVID crises may be over and that the war is won is addressed and redefined as an evolutionary arms race against SARS-CoV-2.

Novavax: Full Steam Ahead

Inmode Ltd

Sorrento Therapeutics Inc

Here are three healthcare stocks as nominees for a quick double in 2021.

3 COVID Stocks That Might Double Soon

The shares of Novavax, Inc (NASDAQ:NVAX) have had an impressive year, more than doubling since Jan. 1, with the 320-day moving average capturing the security's most dramatic pullback in mid-May.

Why Novavax Stock Looks Ready to Rebound

The Novavax vaccine might indeed reduce vaccine hesitancy in the United States. If that's true than NVAX stock may have much more upside than I previously imagined.

Familiarity May Not Breed Contempt When It Comes to Novavax Stock

The shares are lagging behind those of biotech rivals.

Is Novavax a Buy?

With more overseas deals and its potential to still find success domestically in the booster-shot space, big upside remains for NVAX stock. The post Novavax Has More Room to Run as the Vaccination Push Carries On appeared first on InvestorPlace.

News for Novavax Stock (NVAX)